MCF-7 Resistant Doxorubicin are Characterized by Lamelapodia, Strong Adhesion on Substrate and P-gp Overexpression

Dyaningtyas Dewi Pamungkas Putri, Sarmoko Sarmoko, Rifki Febriansah, Endah Puspitasari, Nur Ismiyati, Aditya Fitriasari

Abstract


The prognosis of breast cancer patients is closely associated with the response of tumor cells to chemotherapy agent. Doxorubicin is one of the primary chemotherapeutic agents used for the treatment of breast cancer. Resistance to chemotherapy is believed to cause treatment failure in cancer patients. Furthermore, long time exposure to chemotherapeutic agent induces cancer cells resistance. MCF-7 sensitive cells used as chemoresistance model have overexpression P-gp (P-glycoprotein). Chemoresistance was established by treating MCF-7 cells with 0.5 µg/ml doxorubicin-contained medium for a week. 50% inhibiting concentration (IC50) doxorubicin on MCF-7 cells/DOX were determined using MTT assay. Western blot assay and immunocytochemistry assay was performed to determine the expression of P-gp. Morphological of MCF-7 cell/DOX was changing to become larger and have lamellapodia. IC50 value of doxorubicin was 700 nM on MCF-7/DOX and 400 nM on sensitive MCF-7 cells. The MCF-7/DOX sensitivity to doxorubicin was decreased, shown by 1.5 fold higher IC50 of doxorubicin on MCF-7/DOX compared to MCF-7 sensitive cells. Treatment doxorubicin to sensitive MCF-7 cells leads to the increasing P-gp expression. The P-gp level expression has strong correlation with the low sensitivity of MCF-7/DOX to doxorubicin.

Keywords: doxorubicin, resistance cells, sensitive MCF-7 cell


Full Text:

PDF

References


Coley, H.M., 2009, Mechanisms and Consequences of Chemotherapy Resistance in Breast Cancer, EJC Suppl., 7(1), 3-7. CrossRef

Dean, M., Rzhetsky, A. and Allikmets, R., 2001, The Human ATP-Binding Cassette (ABC) Transporter Superfamily, Genome Res., 11(7), 1156-1166. CrossRef

Gandhi, L., Harding, M.W., Neubauer, M., Langer, C.J., Moore, M., Ross, H.J., Johnson, B.E., and Lynch, T.J., 2007, A Phase II Study of The Safety And Efficacy of The Multidrug Resistance Inhibitor VX-710 Combined With Doxorubicin and Vincristine In Patients with Recurrent Small Cell Lung Cancer, Cancer, 109(5), 924-932. CrossRef

Gottesman, M.M., Fojo, T. and Bates, S.E., 2002, Multidrug Resistance In Cancer: Role Of Atp-Dependent Transporters, Nat. Rev. Cancer, 2(1), 48-58. CrossRef

Higgins, C.F., 2007, Multiple Molecular Mechanisms for Multidrug Resistance Transporters, Nature, 446(7137), 749-757. CrossRef

Kano, T., Wada, S., Morimoto, K., Kato, Y., and Ogihara, T., 2011, Effect of Knockdown of Ezrin, Radixin, and Moesin on P-Glycoprotein Function in Hepg2 Cells, J. Pharm. Sci., 100(12), 5308-5314. CrossRef

Loo, T.W. and Clarke, D.M., 2005, Recent Progress in Understanding The Mechanism of P-Glycoprotein-Mediated Drug Efflux, J. Membr. Biol., 206(3), 173-185. CrossRef

Lukyanova, N.Y., Rusetskya, N.V., Tregubova, N.A. and Chekhun,V.F., 2009, Molecular Profile and Cell Cycle in MCF-& Cells Resistant to Cisplatin dan Doxorubicin, Exp. Oncol., 31(2), 87-91. Link

Michor, F., Nowak, M.A., and Iwasa, Y., 2006, Evolution of Resistance to Cancer Therapy, Curr. Pharm. Des, 12(3), 261-271. Link

Rottner, K., Hall, A. and Small, J.V., 1999, Interplay Between Rac And Rho In The Control Of Substrate Contact Dynamics, Curr. Biol., 9(12), 640-648. Link

Varma, M.V., Ashokraj, Y., Dey, C.S. and Panchagnula, R., 2003, P-Glycoprotein Inhibitors And Their Screening: A Perspective From Bioavailability Enhancement, Pharmacol. Res., 48(4), 347-359. Link

Yang, N., Higuchi, O., Ohashi, K., Nagata, K., Wada, A., Kangawa, K., et al., 1998, Cofilin Phosphorylation by LIM-Kinase 1 and Its Role In Rac-Mediated Actin Reorganization, Nature, 393(6687), 809-812. CrossRef




DOI: http://dx.doi.org/10.14499/indonesianjcanchemoprev2iss3pp304-309

Copyright (c) 2017 Indonesian Journal of Cancer Chemoprevention

Indexed by:

               

               

      

 

Indonesian Society for Cancer Chemoprevention